中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2010年
4期
474-476
,共3页
丙戊酸/投药和剂量%肌萎缩侧索硬化/药物疗法
丙戊痠/投藥和劑量%肌萎縮側索硬化/藥物療法
병무산/투약화제량%기위축측색경화/약물요법
Valproic acid/AD%Amyotrophic lateral sclerosis/DT
目的 研究不同剂量丙戊酸钠对肌萎缩侧索硬化模型鼠发病时间、运动障碍程度以及动物存活时间的影响.方法 筛选鉴定肌萎缩侧索硬化模型鼠(hSOD1-G93A基因型阳性小鼠),将其随机分为治疗组(n=18)及对照组(n=6),治疗组分别给不同剂量浓度丙戊酸钠,对照组给予等剂量的生理盐水.从12周龄起对小鼠运动障碍程度进行评定,直至死亡,记录发病时间及存活时间.结果 高剂量丙戊酸钠可以延迟ALS小鼠发病时间(9.8±1.4)d(P<0.05),可以延长ALS小鼠生存时间(15.5±0.9)d(P<0.05),在改善小鼠运动障碍程度上与对照组比较差异无统计学意义(P>0.05);低、中剂量丙戊酸钠在模型鼠发病时间、生存时间及运动障碍程度上与对照组比较差异均无统计学意义(P>0.05).结论 高剂量丙戊酸钠(VPA 300 mg/kg)可以延迟肌萎缩侧索硬化模型鼠发病时间及延长生存时间,对hSOD1-G93A基因型阳性小鼠运动神经元变性具有保护作用.
目的 研究不同劑量丙戊痠鈉對肌萎縮側索硬化模型鼠髮病時間、運動障礙程度以及動物存活時間的影響.方法 篩選鑒定肌萎縮側索硬化模型鼠(hSOD1-G93A基因型暘性小鼠),將其隨機分為治療組(n=18)及對照組(n=6),治療組分彆給不同劑量濃度丙戊痠鈉,對照組給予等劑量的生理鹽水.從12週齡起對小鼠運動障礙程度進行評定,直至死亡,記錄髮病時間及存活時間.結果 高劑量丙戊痠鈉可以延遲ALS小鼠髮病時間(9.8±1.4)d(P<0.05),可以延長ALS小鼠生存時間(15.5±0.9)d(P<0.05),在改善小鼠運動障礙程度上與對照組比較差異無統計學意義(P>0.05);低、中劑量丙戊痠鈉在模型鼠髮病時間、生存時間及運動障礙程度上與對照組比較差異均無統計學意義(P>0.05).結論 高劑量丙戊痠鈉(VPA 300 mg/kg)可以延遲肌萎縮側索硬化模型鼠髮病時間及延長生存時間,對hSOD1-G93A基因型暘性小鼠運動神經元變性具有保護作用.
목적 연구불동제량병무산납대기위축측색경화모형서발병시간、운동장애정도이급동물존활시간적영향.방법 사선감정기위축측색경화모형서(hSOD1-G93A기인형양성소서),장기수궤분위치료조(n=18)급대조조(n=6),치료조분별급불동제량농도병무산납,대조조급여등제량적생리염수.종12주령기대소서운동장애정도진행평정,직지사망,기록발병시간급존활시간.결과 고제량병무산납가이연지ALS소서발병시간(9.8±1.4)d(P<0.05),가이연장ALS소서생존시간(15.5±0.9)d(P<0.05),재개선소서운동장애정도상여대조조비교차이무통계학의의(P>0.05);저、중제량병무산납재모형서발병시간、생존시간급운동장애정도상여대조조비교차이균무통계학의의(P>0.05).결론 고제량병무산납(VPA 300 mg/kg)가이연지기위축측색경화모형서발병시간급연장생존시간,대hSOD1-G93A기인형양성소서운동신경원변성구유보호작용.
Objective To study the effects of different dosages of valproic acid (VPA) in the disease onset, the level of motor dysfunction and survival time to the amyotrophic lateral sclerosis (ALS) model mice. Methods The ALS model mice (hSOD1-G93A gene positive) was screened and genotyped. Then,the model mice were random divided into treated groups( n = 18) and control group( n =6). The treated groups were i.p. injected with different dosage of VPA, but the control group was given isodose of saline. The assessment of the motor dysfunction stared from 12 weeks after birth and continued till death, the onset time and the survival time were recorded and compared. Results High dosage of VPA can prolong the onset time (9. 8 ± 1.4) days( P <0. 05), survival time ( 15.5 ±0. 9) days( P <0. 05), but it was not statistically significant to improve the motor dysfunction for the model mice. Compared with the control group,low and middle dosage of VPA were not statistically significant to prolong the onset time, the survival time for the model mice, and the level of motor dysfunction. Conclusions High dosage of VPA can delay the onset time of the ALS model mice and prolong the survival time, and which has neuroprotective effects against the neuronal degeneration in the hSOD1-G93A-gene-positive model mice.
